Edesa Biotech Inc Cash Flow Conversion Efficiency
Edesa Biotech Inc cash flow conversion efficiency. Based on the latest financial reports, Edesa Biotech Inc (EDSA) has a cash flow conversion efficiency ratio of -0.346x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.05 Million) by net assets ($8.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Edesa Biotech Inc (2009–2025)
Cash flow conversion efficiency of Edesa Biotech Inc from 2009 to 2025. This chart illustrates how Edesa Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View EDSA share price today for real-time trading data and today's change.
Edesa Biotech Inc Cash Flow Conversion Ratio Explained
Edesa Biotech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Edesa Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edesa Biotech Inc ranked by their cash flow conversion efficiency. Also see EDSA market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acco Group Holdings Limited Ordinary Shares
NASDAQ:ACCL
|
-0.123x |
|
Impact Coatings publ AB
ST:IMPC
|
-0.099x |
|
Hilbert Group AB Series B
ST:HILB-B
|
-0.485x |
|
Mao Bao Inc
TW:1732
|
0.056x |
|
Alakasa Industrindo Tbk
JK:ALKA
|
0.034x |
|
RYTHM, Inc.
NASDAQ:RYM
|
0.221x |
|
Cineverse Corp.
NASDAQ:CNVS
|
-0.025x |
|
Pakka Limited
NSE:PAKKA
|
0.068x |
Annual Cash Flow Conversion Efficiency for Edesa Biotech Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Edesa Biotech Inc from 2009 to 2025. Review Edesa Biotech Inc (EDSA) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $12.45 Million | $-7.32 Million | -0.588x | +76.18% |
| 2024-09-30 | $1.98 Million | $-4.89 Million | -2.468x | -162.17% |
| 2023-09-30 | $7.05 Million | $-6.64 Million | -0.942x | +27.99% |
| 2022-09-30 | $9.39 Million | $-12.28 Million | -1.308x | -24.95% |
| 2021-09-30 | $13.06 Million | $-13.66 Million | -1.046x | -91.15% |
| 2020-09-30 | $9.11 Million | $-4.99 Million | -0.547x | +40.62% |
| 2019-09-30 | $5.26 Million | $-4.85 Million | -0.922x | -125.45% |
| 2018-09-30 | $11.29 Million | $-4.62 Million | -0.409x | +35.62% |
| 2017-09-30 | $7.40 Million | $-4.70 Million | -0.635x | -73.60% |
| 2016-09-30 | $12.31 Million | $-4.51 Million | -0.366x | +33.62% |
| 2015-09-30 | $8.01 Million | $-4.41 Million | -0.551x | +0.52% |
| 2014-09-30 | $7.70 Million | $-4.27 Million | -0.554x | -159.51% |
| 2013-09-30 | $-3.14 Million | $-2.92 Million | 0.931x | +120.08% |
| 2012-09-30 | $851.61K | $-3.95 Million | -4.636x | -713.47% |
| 2011-09-30 | $4.59 Million | $-2.62 Million | -0.570x | -92.42% |
| 2010-09-30 | $2.47 Million | $-732.23K | -0.296x | -281.29% |
| 2009-09-30 | $484.95K | $-37.67K | -0.078x | -- |
About Edesa Biotech Inc
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-… Read more